Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

By U. Nagele, Karl-Dietrich Sievert, M. Kuczyk, Arnulf Stenzl. European Urology, 2006

2,973 citations recorded by the source corpus.

Subfields: Epidemiology, Surgery, Urology

View Paper: https://www.semanticscholar.org/paper/e0ae4d00a20344bca75f141d0dd97510461b986b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

1. M. Burger
2. M. Rouprêt
3. M. Babjuk
4. B. V. van Rhijn
5. S. Shariat
6. R. Sylvester

Citations in the corpus

• Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. (2009, methodology): “In an attempt to individualise prediction of recurrence, Sylvester et al [15] calculated the probability of recurrence using data from 2596 patients who participated in seven European Organisation for Research and Treatment of Cancer (EORTC) trials.”
• European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). (2021, methodology): “Detection of concurrent CIS increases the risk of recurrence and progression of Ta/T1 tumours [71,73].”
• Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. (2016, methodology): “A widely published system is the European Organizat ion for Research and Treatment of Cancer (EORTC) risk calculator, based on the combined data from seven trials involving patients with NMIBC.(13) The EORTC calculator provides a probability of rec urrence and progression at one and five years.”
• European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. (2019, background): “Detection of concurrent CIS increases the risk of recurrence and progression of TaT1 tumours [62,64]; in this case, further treatment according to the criteria summarised in sections 3.”
• Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. (2009, methodology): “factors that allows urologists to easily predict the risk of short-term and long-term recurrence and progression to muscle invasive disease.(3) However, a small percent of patients in that series was treated with BCG.”
• Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions (2017, background): “Even though mortality is low, recurrence and disease progression rates are relatively high [233].”
• EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. (2017, methodology): “To predict separately the short- and long-term risks of disease recurrence and progression in individual patients, the European Organisation for the Research and Treatment of Cancer-Genito-Urinary Cancer Group (EORTC-GUCG) developed a scoring system and risk tables [56].”